Loading company…
Suzhou Baimai Biopharmaceutical develops biomaterial-based drugs and immunotherapy treatments.
The company develops drug candidates for oncology and cancer, including BM201, BM101, BM221, and BM501. Established in 2019, it is based in Suzhou, China; BM201 has been approved for IND and is preparing to enter Phase I clinical trials.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in